All News

US.hand_.jpg

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

d David Liew, FRACP

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rhe

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2019 Report – Day 2

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day two at EULAR 2019.

Read Article
eye%20exa.jpg (keep)

Blinded by the Use of Antimalarials in Lupus?

d Janet Pope, MD, MPH, FRCPC

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR gui

Read Article
Conv3.jpg

EULAR 2019 - Day 1 Report

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.

Read Article
vitamins.png

CAM Use is Common in Psoriasis

d Jack Cush, MD

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Prevalence of Methotrexate Toxicities (6.28.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
falls.jpg (keep)

Mortality from Falls in the Elderly

d Jack Cush, MD

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age. 

Read Article
Lupus.survival.MMWR_.2019.png

Disparities in Lupus Survival

d Jack Cush, MD

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively).

Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

Read Article
Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p

Links:

Dr. John Cush RheumNow ( View Tweet)

14 patient pilot study presented by Dr. Genovese; once daily vagal stimulation worked but 4 times daily did not! https://t.co/TUWr7fT7x3

Links:

Dr. John Cush RheumNow ( View Tweet)

FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. Small incremental response when dose is escalated, and radiographic progression is low. #eular2019 @RheumNow

Alberta Hoi tuna0sashimi ( View Tweet)

Men with #gout are severely under treated, under educated and unmotivated to better manage their gout! https://t.co/icdDIUSdJb

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 https://t.co/UtvBLz6Cg7 https://t.co/tptDVbBug2

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA (Stills) patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/9mtxPkHZr3
Dr. John Cush RheumNow ( View Tweet)
We need to talk about repeated ANAs - good lessons from the plenary hall today about 7875 repeated ANA tests from a single center. #EULAR2019 OP0020 by Ai Li Yeo @RheumNow @MonashHealth @earlyARA @ChooseWiselyAU https://t.co/j00DDKuZFt
David Liew drdavidliew ( View Tweet)
795 RA patients from the GIRRCS cohort 3 yr study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is UP! Discussions of MTX stomatitis, Loading doses, PPD Shortage, infection risk from steroids or THR/TKR and more. Watch it here>> https://t.co/8koj2HG4RC or listen in on iTunes or SoundCloud >> https://t.co/0EXaXq2l7G

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has announced that on July 25th it will hold an Arthritis Advisory Committee Meeting to discuss Boehringer Ingelheims application for Nintedanib use in systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX

Links:

Dr. John Cush RheumNow ( View Tweet)

What’s next in biosimilars? Visit RheumNow to listen to experts discuss this and more in "Therapeutic Update: Biosimilars in Rheumatology," a video series sponsored by Sandoz, Inc. https://t.co/1vmnEJqOSi #sponsored

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 3954 studies, 20 RCTs examined MTX toxicity and found the prevalence of alopecia to be 1- 4.9% and the prevalence of stomatitis to be between 5.7-8% https://t.co/LHbAYvV71X

Links:

Dr. John Cush RheumNow ( View Tweet)

×